Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28347572 | 1.00 | PDE4D (0.35) | PDE4DKDM4EMAPTNPSR1IGF1R | |
| SCHEMBL20489256 | 0.88 | KDM4E (0.35) | KDM4ENPSR1LMNAGFERALDH1A1 | |
| SCHEMBL20489255 | 0.88 | KDM4E (0.35) | KDM4ENPSR1LMNAGFERALDH1A1 | |
| SCHEMBL21791604 | 0.72 | P2RX7 (0.42) | KDM4ENPSR1HSD17B10LMNAGFER | |
| SCHEMBL18209663 | 0.72 | PDE4D (0.45) | PDE4DKDM4EMAPTNPSR1IGF1R | |
| SCHEMBL2922516 | 0.68 | MEN1 (0.39) | MAPTALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL13058172 | 0.68 | MEN1 (0.39) | MAPTALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL2922518 | 0.68 | MEN1 (0.39) | MAPTALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL27892352 | 0.67 | TDP1 (0.39) | TDP1 | |
| SCHEMBL2919446 | 0.67 | TDP1 (0.45) | TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-03-05 | — | — | US | disclosed |
| CN-110709385-A | Haloallylamine pyrazole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2020-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, AADAC | PDE4D 684/4885KDM4E 647/4885MAPT 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.